Navigation Links
Results of world's first gene therapy trial for arthritis show approach safe, feasible

en that gene therapy was so new and we were dealing with an otherwise healthy patient population, the ex vivo protocol was the most appropriate approach to take at the time," stated Paul Robbins, Ph.D., professor of molecular genetics and biochemistry and orthopaedic surgery at the University of Pittsburgh School of Medicine, who was the study's co-principal investigator and then director of the University of Pittsburgh's Viral Vector Core Facility.

According to their results, joints treated with the genetically modified cells exhibited high levels of IL-1 Ra, indicating successful gene transfer. Clusters of cells that expressed large amounts of the gene were present at the surface of the synovial tissue and produced significantly less of the inflammation-provoking IL-6 and PGE 2 than cells within joints that were not treated with the gene.

The nine women enrolled in the trial were between 49 and 73 years of age and had been living with rheumatoid arthritis for between 10 and 26 years. Each was scheduled for joint replacement surgery involving the four knuckles on one of their hands and one additional joint. In the weeks prior to joint replacement surgery, synovial tissue was removed from the additional joint that required surgery. Cells from the tissue were then cultured for several weeks, after which time half the cells had the IL-1 Ra gene inserted and half remained untreated. Six to seven weeks later, following extensive laboratory screening of the genetically modified cells, patients returned to the clinic, where the cells were injected into four knuckles in a double-blind fashion, with two knuckles receiving the gene-modified cells, and two knuckles receiving injections of cells with no added gene. One week later, at the time of the patient's previously scheduled surgery, the four knuckles were removed for study and replaced with artificial joints.

In their animal studies that preceded the clinical trial, the researchers had noted that
'"/>

Source:Brigham and Women's Hospital


Page: 1 2 3 4

Related biology news :

1. Combating anthrax: Results of study published this month as researchers look for a better vaccine
2. Results with newer bladeless LASIK equivalent to standard microkeratome LASIK
3. PCRM develops worlds first cruelty-free insulin assay
4. Breakthrough: Scientists create worlds tiniest organic particles
5. Environmental lessons from tsunami as worlds coastal population doubles
6. New plant DNA libraries provides massive boost to worlds plant researchers
7. New book highlights worlds borderless conservation areas
8. Some good news for the worlds poor
9. New study of the worlds smallest elephant
10. The worlds deepest dinosaur finding - 2256 metres below the seabed
11. Scientists a step closer to protecting worlds most important crop
Post Your Comments:
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... - Animals that choose to eat in the presence of a ... go into a defensive mode and pay a physical penalty for ... crop pest hornworm caterpillar, a study shows. While other animals ... hornworm caterpillars slow or stop eating but actually keep up their ...
... to participate in ELIXIR ( www.elixir-europe.org ), a major ... in Europe. With one of Europe,s larger economies now ... is well placed to continue its excellent progress. ... infrastructure for managing biological data to support research and ...
... the IRCM, led by geneticist Dr. Jacques Drouin, recently ... inflammation. This important breakthrough will be published in tomorrow,s ... . IRCM scientists study glucocorticoids, a class ... reduce inflammation. They are used in medicine to treat ...
Cached Biology News:Caterpillar gets more from its food when predator is on the prowl 2Italy pledges to be part of ELIXIR research infrastructure 2Controlling inflammatory and immune responses 2
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy ... of donor stem cells for dogs with osteoarthritis. Dr. ... has performed clinical stem cell therapy for 7 years. ... if a single injection of donor stem cells into ... pain and inflammation in the treated joints. , ...
(Date:10/19/2014)... CAMBRIDGE, Mass. , Oct. 19, 2014 NextCODE ... of the whole genome in real time, today announced the ... the NextCODE Exchange , at the American Society of ... . To learn more, sign up and apply for ... on its unique features and benefits can be viewed ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asia-Pacific ... Analytics market in Asia-Pacific with analysis and forecast of ... million in 2014 to $208 million by 2019, at ... 2014 to 2019. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... 2014 The report "Unmanned Ground ... Security), Technology, Payload, Type & by Geography - ... global unmanned ground vehicle market into various sub ... market sizes. The report also identifies the factors ... it along with the adoption trends. , The ...
Breaking Biology Technology:Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5
... , EXTON, Pa., July 15 ... and Cancer Innovations, Inc. (CII), a privately held biotechnology company ... they have entered into an evaluation and option agreement in ... , , The ...
... , , MADISON, Wis., ... (CDI) today announced that it has exclusively in-licensed a US-issued patent portfolio ... cells (cardiomyocytes) in drug testing. , , ... and Indiana University-Purdue University Indianapolis (IUPUI), covers ...
... , PRINCETON, N.J., July 15 ... license agreement with Merck KGaA, Darmstadt, Germany, providing the global ... platform for the research, development and commercialization of their antibody ... , "We are extremely pleased about ...
Cached Biology Technology:Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 2Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 3Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing 2Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing 3BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA 2